CRIS Current Research Information System

DI NUNNO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.740
AS - Asia 2.705
EU - Europa 1.366
AF - Africa 209
Continente sconosciuto - Info sul continente non disponibili 176
SA - Sud America 171
OC - Oceania 4
Totale 7.371
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.682
SG - Singapore 816
VN - Vietnam 710
CN - Cina 615
IT - Italia 286
GB - Regno Unito 201
HK - Hong Kong 182
SE - Svezia 178
DE - Germania 149
BR - Brasile 113
NL - Olanda 91
FR - Francia 90
SC - Seychelles 87
RU - Federazione Russa 83
KR - Corea 76
IN - India 74
IE - Irlanda 72
CH - Svizzera 58
BD - Bangladesh 52
JP - Giappone 51
FI - Finlandia 49
CI - Costa d'Avorio 46
ZA - Sudafrica 29
TG - Togo 28
AR - Argentina 25
CA - Canada 24
ID - Indonesia 23
PH - Filippine 21
BG - Bulgaria 17
MX - Messico 16
BE - Belgio 15
TH - Thailandia 15
AT - Austria 13
EE - Estonia 12
JO - Giordania 11
PL - Polonia 11
UA - Ucraina 11
EC - Ecuador 9
TR - Turchia 9
TW - Taiwan 9
ES - Italia 8
PK - Pakistan 8
MY - Malesia 7
UZ - Uzbekistan 7
NG - Nigeria 6
SA - Arabia Saudita 6
VE - Venezuela 6
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
IQ - Iraq 4
LT - Lituania 4
PE - Perù 4
BB - Barbados 3
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
DZ - Algeria 3
EG - Egitto 3
JM - Giamaica 3
BY - Bielorussia 2
KG - Kirghizistan 2
MK - Macedonia 2
NI - Nicaragua 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
SV - El Salvador 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
CD - Congo 1
CZ - Repubblica Ceca 1
EU - Europa 1
GE - Georgia 1
GN - Guinea 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
NO - Norvegia 1
OM - Oman 1
Totale 7.197
Salva come PNG Salva come JPEG
Città #
Singapore 590
Ashburn 310
Chandler 239
Santa Clara 181
San Jose 179
Hong Kong 166
Fairfield 150
Hanoi 148
Southend 144
Hefei 143
Ho Chi Minh City 139
Beijing 90
Council Bluffs 89
Seattle 81
Houston 73
Dublin 72
Princeton 72
Boardman 70
Woodbridge 67
Dong Ket 65
Seoul 65
Wilmington 60
Bern 55
Los Angeles 53
Cambridge 52
Ann Arbor 49
Lauterbourg 48
Abidjan 46
Helsinki 45
Bologna 42
New York 34
Tokyo 33
Milan 32
Da Nang 30
Buffalo 28
Lomé 28
Berlin 25
Dallas 25
Frankfurt am Main 23
Haiphong 22
Chicago 20
Redondo Beach 20
Sofia 17
London 16
Westminster 16
São Paulo 15
Jakarta 14
Tianjin 14
Bengaluru 13
Brussels 13
Guangzhou 13
Shanghai 13
Turin 13
Johannesburg 12
Redwood City 12
Amman 11
Des Moines 11
Nanjing 10
Naples 10
Rome 10
Biên Hòa 9
Florence 9
Olalla 9
Redmond 9
Boston 8
Denver 8
Falkenstein 8
Falls Church 8
Hải Dương 8
Orem 8
Phoenix 8
San Diego 8
San Francisco 8
Thái Bình 8
Yubileyny 8
Boydton 7
Brooklyn 7
Montreal 7
Warsaw 7
Zhengzhou 7
Changsha 6
Glasgow 6
Hangzhou 6
Shenyang 6
Shenzhen 6
Thái Nguyên 6
Xi'an 6
Bühl 5
Bắc Ninh 5
Bến Tre 5
Cardiff 5
Forlì 5
Harbin 5
Jinan 5
Kyoto 5
Manila 5
Memphis 5
Montescudo 5
Nha Trang 5
Padua 5
Totale 4.402
Salva come PNG Salva come JPEG
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 232
Circulating tumor cells in genitourinary tumors 220
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 209
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 198
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 188
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 178
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 171
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 167
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 166
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 164
Glioblastoma: Emerging treatments and novel trial designs 162
Immune checkpoint inhibitors for metastatic bladder cancer 159
The clinical and prognostic role of ALK in glioblastoma 157
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 153
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 148
The human microbiota and prostate cancer: Friend or foe? 146
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 145
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 139
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 139
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 138
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 136
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 133
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 133
Idh1 non-canonical mutations and survival in patients with glioma 132
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 129
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 128
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 126
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 123
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 121
How to predict progression-free survival in patients with grade 2 IDH-mutated diffuse gliomas after surgery: a long-term follow-up analysis 119
Machine learning in neuro-oncology: toward novel development fields 115
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 114
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 113
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 112
Rare Primary Central Nervous System Tumors in Adults: An Overview 110
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 109
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 108
Gender- and Grade-Dependent Activation of Androgen Receptor Signaling in Adult-Type Diffuse Gliomas: Epigenetic Insights from a Retrospective Cohort Study 103
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 101
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 100
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 100
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 96
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 93
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 85
Targeting Mitochondria in Glioma: New Hopes for a Cure 75
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 74
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 74
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 71
Cabazitaxel in metastatic prostate cancer 64
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 59
Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study 57
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 53
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 52
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 50
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 40
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 37
Immunohistochemical Characterization of Tumor Microenvironment Analysis in Glioblastoma IDH-Wildtype 34
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 34
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 33
N-Myc a key gene promoting a worst prostate cancer progression 31
Future perspectives for personalized immunotherapy in renal cell carcinoma 30
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study 25
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 23
null 22
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 21
MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas 20
Totale 7.371
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.663
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.663
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022597 0 18 15 24 53 22 9 61 56 59 187 93
2022/2023974 90 106 42 100 64 120 28 67 181 37 52 87
2023/2024309 44 62 25 34 19 45 17 26 8 18 2 9
2024/20251.229 65 165 108 86 236 62 64 34 9 115 79 206
2025/20263.141 231 354 266 213 298 151 388 146 571 249 174 100
2026/2027226 88 138 0 0 0 0 0 0 0 0 0 0
Totale 7.371